X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11432) 11432
Publication (1976) 1976
Book Review (135) 135
Book Chapter (103) 103
Conference Proceeding (35) 35
Dissertation (33) 33
Book / eBook (5) 5
Government Document (4) 4
Data Set (3) 3
Magazine Article (2) 2
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7349) 7349
mtor (6752) 6752
humans (6163) 6163
animals (4004) 4004
oncology (3254) 3254
rapamycin (2994) 2994
cancer (2790) 2790
tor serine-threonine kinases - metabolism (2698) 2698
mammalian target (2421) 2421
mice (2402) 2402
female (2203) 2203
cell biology (2165) 2165
apoptosis (2136) 2136
phosphorylation (2110) 2110
signal transduction (2001) 2001
male (1980) 1980
cell line, tumor (1920) 1920
tor serine-threonine kinases - antagonists & inhibitors (1849) 1849
signal transduction - drug effects (1734) 1734
autophagy (1731) 1731
proteins (1651) 1651
activation (1598) 1598
akt (1582) 1582
sirolimus - pharmacology (1471) 1471
kinases (1469) 1469
biochemistry & molecular biology (1455) 1455
expression (1422) 1422
proto-oncogene proteins c-akt - metabolism (1388) 1388
growth (1379) 1379
everolimus (1352) 1352
pathway (1203) 1203
article (1200) 1200
research (1125) 1125
tor protein (1110) 1110
cell proliferation - drug effects (1093) 1093
inhibition (1033) 1033
tor serine-threonine kinases (1012) 1012
analysis (977) 977
mtor inhibitors (959) 959
apoptosis - drug effects (933) 933
pharmacology & pharmacy (929) 929
pi3k (927) 927
phosphatidylinositol 3-kinases - metabolism (923) 923
middle aged (882) 882
care and treatment (873) 873
tumors (868) 868
antineoplastic agents - pharmacology (867) 867
sirolimus - analogs & derivatives (828) 828
health aspects (826) 826
mtor inhibitor (811) 811
cell proliferation (769) 769
gene expression (752) 752
adult (751) 751
metabolism (721) 721
cell growth (715) 715
cells (715) 715
therapy (715) 715
chemotherapy (709) 709
antineoplastic agents - therapeutic use (700) 700
aged (698) 698
protein kinase inhibitors - pharmacology (696) 696
sirolimus - therapeutic use (690) 690
tor serine-threonine kinases - genetics (689) 689
rats (680) 680
mechanistic target of rapamycin complex 1 (678) 678
cell cycle (675) 675
breast cancer (664) 664
metastasis (664) 664
biology (644) 644
physiological aspects (633) 633
genetic aspects (603) 603
mutation (594) 594
proliferation (592) 592
sirolimus (589) 589
medicine, research & experimental (587) 587
cells, cultured (581) 581
survival (581) 581
neurosciences (580) 580
autophagy - drug effects (579) 579
research article (577) 577
phosphatidylinositol 3-kinases - antagonists & inhibitors (576) 576
in-vitro (571) 571
xenograft model antitumor assays (557) 557
signaling pathway (546) 546
kinase (545) 545
akt protein (542) 542
cell line (526) 526
medicine (523) 523
cancer therapies (510) 510
dose-response relationship, drug (504) 504
protein kinases - metabolism (504) 504
inhibitors (501) 501
development and progression (498) 498
multidisciplinary sciences (493) 493
treatment outcome (493) 493
mammalian target of rapamycin (491) 491
sirolimus - administration & dosage (491) 491
breast-cancer (490) 490
phosphorylation - drug effects (485) 485
mtor pathway (478) 478
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11293) 11293
French (100) 100
German (51) 51
Spanish (26) 26
Chinese (15) 15
Russian (15) 15
Korean (13) 13
Japanese (12) 12
Polish (11) 11
Czech (5) 5
Hungarian (5) 5
Turkish (3) 3
Slovak (2) 2
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cell, ISSN 1097-2765, 2011, Volume 44, Issue 2, pp. 304 - 316
DEPTOR, an inhibitor of mTORC1 and mTORC2, is degraded via ubiquitin-proteasome pathway by an unknown E3 ubiquitin ligase. Here we report that DEPTOR is a... 
CANCER-CELLS | TARGET | IN-VITRO | COMPLEX | PATHWAY | BIOCHEMISTRY & MOLECULAR BIOLOGY | F-BOX PROTEINS | DEGRADATION | CELL-GROWTH | KAPPA-B | PROMOTES | CELL BIOLOGY | mTOR | SCF E3 ligase | DEPTOR | Autophagy | βTrCP | survival
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2018, Volume 142, Issue 1, pp. 202 - 213
Mantle cell lymphoma (MCL) is an aggressive and incurable malignant disease. Despite of general chemotherapy, relapse and mortality are common, highlighting... 
mTOR inhibitor | targeted therapy | BTK inhibitor | drug combination | Mantle cell lymphoma | UNITED-STATES | ACTIVATION | PHOSPHORYLATION | PLUS RITUXIMAB | IBRUTINIB | PROLIFERATION | COMBINATION | ONCOLOGY | RESISTANCE | CHRONIC LYMPHOCYTIC-LEUKEMIA | SGK1 | Everolimus - pharmacology | Apoptosis - drug effects | Humans | Lymphoma, Mantle-Cell - drug therapy | Drug Synergism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Proliferation - drug effects | Mice | Acrylamides - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Proteins | Tyrosine | Chemotherapy | Analysis | Mortality | Phenols | Lymphomas | Drug therapy, Combination | Gene expression | Cancer | Drugs | Regulators | Animal models | Bax protein | AKT protein | Drug development | Kinases | B-cell receptor | Cyclin D1 | Caspase-3 | Phase transitions | Cyclin-dependent kinase 4 | Anticancer properties | Signal transduction | Antitumor agents | Bcl-x protein | Xenografts | Cell cycle | Inhibition | Mantle | G1 phase | Phase transformations | Poly(ADP-ribose) polymerase | Caspase | Pharmacology | Rapamycin | Lymphoma | Bruton's tyrosine kinase | Cyclin-dependent kinase 2 | Signaling | Inhibitors | Lymphocytes B | Cell lines | Bcl protein | Synergistic effect | Apoptosis | Index Medicus
Journal Article
Liver International, ISSN 1478-3223, 05/2013, Volume 33, Issue 5, pp. 780 - 793
Journal Article
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 08/2014, Volume 90, Issue 3, pp. 197 - 207
While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous... 
mTOR | AKT | SQCLC | PI3K | NSCLC | MAMMALIAN TARGET | I PI3K INHIBITOR | ONCOGENE MUTATIONS | AKT INHIBITOR | ANTITUMOR-ACTIVITY | DOSE-ESCALATION | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | ADVANCED NSCLC | PHASE-I | MTOR INHIBITOR | Lung Neoplasms - drug therapy | TOR Serine-Threonine Kinases - metabolism | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Enzyme Inhibitors - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Enzyme Inhibitors - adverse effects | Molecular Targeted Therapy - adverse effects | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - metabolism | Enzyme Inhibitors - therapeutic use | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2017, Volume 16, Issue 5, pp. 793 - 804
Journal Article
Journal Article
Liver International, ISSN 1478-3223, 04/2015, Volume 35, Issue 4, pp. 1451 - 1463
Background & Aims Mammalian target of rapamycin and angiotensin‐converting enzyme inhibition has been shown to have antifibrotic activity in models of liver... 
mTOR inhibitors | fibrosis | Mdr2 | ACE inhibitors | MTOR inhibitors | Fibrosis | RAPAMYCIN | BILE-DUCT | LIVER FIBROSIS | BILIARY FIBROSIS | HEPATIC-FIBROSIS | P-GLYCOPROTEIN | IN-VITRO | SCLEROSING CHOLANGITIS | SMOOTH-MUSCLE-CELLS | GASTROENTEROLOGY & HEPATOLOGY | SIROLIMUS | Liver - pathology | Liver - enzymology | Tetrazoles - pharmacology | Captopril - pharmacology | Species Specificity | TOR Serine-Threonine Kinases - metabolism | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Male | Liver Cirrhosis, Experimental - drug therapy | Angiotensin II Type 1 Receptor Blockers - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Liver Cirrhosis, Experimental - enzymology | Biphenyl Compounds - pharmacology | Liver - drug effects | Time Factors | Liver Cirrhosis, Experimental - pathology | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Drug Therapy, Combination | Everolimus - pharmacology | Hydroxyproline - metabolism | Gene Expression Regulation | Liver Cirrhosis, Experimental - genetics | Sirolimus - pharmacology | Mice, Knockout | Animals | Signal Transduction - drug effects | Renin-Angiotensin System - drug effects | Protein Kinase Inhibitors - pharmacology | ATP Binding Cassette Transporter, Sub-Family B - genetics | Liver diseases | Captopril | Analysis | Angiotensin | Genetic research | Gene expression
Journal Article